Richard E. Uihlein - Jan 24, 2022 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
Director, 10%+ Owner
Signature
Jack W. Callicutt
Stock symbol
GALT
Transactions as of
Jan 24, 2022
Transactions value $
$35,000
Form type
4
Date filed
2/8/2022, 08:25 AM
Previous filing
Jan 25, 2022
Next filing
Jan 30, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GALT Common Stock Award $35K +17.7K +0.22% $1.98 7.94M Jan 24, 2022 Direct F1
holding GALT Common Stock 27.7K Jan 24, 2022 By Ed Uihlein Family Foundation F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Stock Option (right to buy) Award $0 +40K $0.00 40K Jan 24, 2022 Common Stock 40K $1.98 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $35,000 for 2022. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2022.
F2 The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934.
F3 The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.
F4 The options vest 100% on December 31, 2022.